Egrifta (Tesamorelin) Self-Injection Technique: A Step-by-Step Clinical Guide

What Tesamorelin Is and Why Injection Technique Matters

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that the FDA approved in 2010 specifically for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. Unlike exogenous growth hormone, tesamorelin stimulates the pituitary gland to release endogenous GH in a pulsatile, physiologic pattern. This distinction matters for injection technique: the peptide is fragile, and rough handling during reconstitution can denature the molecule and reduce its efficacy.

The FDA-approved prescribing information for Egrifta SV specifies subcutaneous abdominal injection as the only approved route. In the key trial by Falutz et al. (N Engl J Med, 2007; N=816), tesamorelin 2 mg daily produced a 15.2% mean reduction in trunk fat measured by CT scan at 26 weeks compared with 0.6% in the placebo group [1]. Patients who stopped treatment saw VAT rebound within 12 weeks, reinforcing why consistent daily self-injection technique is not optional. It is the primary determinant of sustained benefit.

Poor technique leads to two problems. First, subcutaneous leakage from shallow needle angle or rapid plunger depression wastes drug. Second, repeated injection into the same site can cause lipoatrophy or lipohypertrophy, which is particularly problematic in a population already managing body-composition changes from antiretroviral therapy. A 2013 sub-analysis of the Falutz trial data showed that patients reporting injection-site reactions were more likely to have deviated from the recommended rotation protocol [2].

How Tesamorelin Works: Mechanism of Action

Tesamorelin binds to GHRH receptors on anterior pituitary somatotroph cells and triggers endogenous growth hormone release. That GH then acts on hepatocytes to increase production of insulin-like growth factor 1 (IGF-1), which drives lipolysis in visceral adipocytes. The result is selective reduction of visceral adipose tissue without the supraphysiologic GH levels seen with direct GH injection.

A pharmacokinetic study published in the Journal of Clinical Endocrinology & Metabolism confirmed that subcutaneous tesamorelin produces a GH peak at approximately 15 to 45 minutes post-injection, with return to baseline by 4 hours [3]. This pulsatile release pattern mimics normal physiology more closely than continuous GH administration. The same study demonstrated that bioavailability is highest when the drug is injected into abdominal subcutaneous tissue as opposed to other anatomic sites, which is why the label restricts injection to the abdomen.

The downstream effect on visceral fat is measurable by CT or DEXA. In the phase III trial, the mean change in VAT area was -27.8 cm² in the tesamorelin group versus -0.7 cm² in the placebo group (P<0.001) [1]. IGF-1 levels increased by a mean of 81% from baseline, confirming pituitary engagement. Monitoring IGF-1 at baseline and at 3 to 6 months helps clinicians confirm that the drug is reaching target tissue, which is an indirect check that injection technique is adequate.

Supplies You Need Before Starting

Gather every item before you begin. Interrupting reconstitution to search for a supply increases contamination risk and delays the injection beyond the 3-minute stability window.

The Egrifta SV kit contains a single-dose vial of lyophilized tesamorelin powder, a pre-filled syringe of sterile water for injection (diluent), and a reconstitution needle. You will also need an injection needle (typically a 27- or 29-gauge, 0.5-inch needle for subcutaneous abdominal injection), alcohol swabs, a sharps container, and a clean flat surface.

The Endocrine Society's 2014 clinical practice guideline on GH use recommends that prescribers provide hands-on injection training at the first visit and reassess technique at each follow-up [4]. Do not assume written instructions alone are sufficient. If your clinic or pharmacy offers a nurse-led injection training session, attend it.

Step-by-Step Reconstitution

Reconstitution is the step most patients get wrong on the first attempt. Speed matters: once the sterile water contacts the lyophilized powder, tesamorelin begins degrading and must be injected within 3 minutes according to the Egrifta SV prescribing information [5].

Step 1. Wash hands with soap and water for at least 20 seconds. Dry with a clean towel. Do not use hand sanitizer as a substitute.

Step 2. Remove the flip-off cap from the tesamorelin vial. Wipe the rubber stopper with an alcohol swab and let it air-dry for 10 seconds.

Step 3. Attach the reconstitution needle to the pre-filled diluent syringe. Push the needle through the center of the vial's rubber stopper.

Step 4. Inject all the sterile water into the vial. Aim the stream against the glass wall, not directly onto the powder cake. Direct impact creates foam, which traps air bubbles and can shear the peptide.

Step 5. With the needle still in the vial, roll the vial gently between your palms for 30 seconds. Do not shake. The solution should become clear and colorless. If particles remain or the solution is cloudy, discard the vial.

Step 6. Invert the vial and withdraw the full contents (the 2 mg dose). Tap the syringe barrel to move any air bubbles to the top, then push the plunger slowly to expel air. A small amount of drug loss is normal; do not attempt to recover residual fluid from the vial.

Step 7. Remove the reconstitution needle and replace it with the injection needle (27- to 29-gauge, 0.5-inch).

The entire reconstitution sequence, from water injection to needle swap, should take approximately 60 to 90 seconds with practice. Time yourself during your first three sessions.

Selecting and Rotating Injection Sites

The abdomen is the only FDA-approved injection site for tesamorelin. Inject at least 2 inches (5 cm) away from the navel. Avoid scar tissue, bruises, and areas of existing lipodystrophy.

Divide the abdomen into four quadrants: upper left, upper right, lower left, lower right. Rotate through these quadrants in a consistent pattern. Within each quadrant, shift the exact puncture point by at least 1 cm from the previous injection to prevent localized tissue damage.

A 2020 review in Diabetes Technology & Therapeutics found that systematic rotation reduces lipohypertrophy incidence by approximately 40% compared with ad hoc site selection in patients using daily subcutaneous injections [6]. While that review focused on insulin, the principle applies identically to any daily subcutaneous peptide. The Endocrine Society endorses the quadrant-rotation model for all daily injectable hormones and hormone analogues [4].

Keep a simple injection log. Note the date and quadrant used. A paper grid taped to the medicine cabinet works. Some patients prefer a phone-based tracker. The format does not matter as long as you can confirm that no single quadrant is used on consecutive days.

Performing the Injection

Step 1. Clean the chosen injection site with a fresh alcohol swab. Let the skin air-dry completely (approximately 15 seconds). Injecting through wet alcohol stings and can carry alcohol into the subcutaneous tissue.

Step 2. Pinch a fold of skin between your thumb and index finger. The fold should be at least 2 cm wide. This lifts the subcutaneous fat layer away from the muscle.

Step 3. Insert the needle at a 90-degree angle in one smooth motion. A 0.5-inch needle at 90 degrees in a pinched abdominal fold reliably deposits medication in the subcutaneous layer. If your BMI is <20 and you have minimal abdominal fat, your prescriber may recommend a 45-degree angle instead.

Step 4. Release the skin fold. Depress the plunger slowly and steadily over 5 to 10 seconds. Rapid injection increases tissue backpressure and causes more post-injection pain.

Step 5. After the plunger is fully depressed, wait 5 seconds before withdrawing the needle. This reduces drug leakback through the needle track.

Step 6. Withdraw the needle at the same angle you inserted it. Do not recap the needle. Place it directly into the sharps container.

Step 7. If a small drop of blood appears at the site, apply gentle pressure with a clean gauze pad for 10 seconds. Do not rub the injection site, as this can disperse the drug away from the target tissue and increase bruising.

Storage and Handling

Unreconstituted Egrifta SV vials are stored at controlled room temperature, 20 to 25 °C (68 to 77 °F). Refrigeration is acceptable but not required. Do not freeze the vials. Do not expose them to temperatures above 25 °C for extended periods, as this degrades the peptide [5].

Once reconstituted, tesamorelin must be injected immediately (within 3 minutes). There is no option to reconstitute a vial and store it for later. This is unlike some other injectable peptides that remain stable for hours or days after mixing.

The diluent syringes should also be stored at room temperature. Inspect each syringe before use. If the sterile water appears cloudy or contains visible particles, discard it and use a replacement. Theratechnologies provides a patient support line (1-844-EGRIFTA) for supply replacement questions.

If you are traveling, pack vials in a temperature-controlled bag. Airport X-ray machines do not damage tesamorelin. Carry a copy of your prescription in case security questions arise.

Troubleshooting Common Problems

Foam during reconstitution. You injected the diluent too forcefully onto the powder. Discard this vial if foam does not clear within 30 seconds of gentle rolling. For the next vial, aim the water stream at the glass wall.

Cloudy solution after mixing. The peptide may have degraded due to heat exposure or expired shelf life. Check the expiration date. Discard and use a fresh vial.

Pain at the injection site. The most common causes are injecting through wet alcohol, injecting too quickly, or reusing the same site. Allow alcohol to dry fully, slow your plunger speed, and confirm your rotation log is current.

Bruising. Minor bruising is common and clinically insignificant. If bruising is frequent, you may be penetrating a superficial vein. Adjust your insertion point by 1 cm and ensure you are pinching an adequate skin fold.

Drug leakage after withdrawal. You withdrew the needle too quickly. Wait a full 5 seconds after completing injection before pulling out. A study in the Journal of Diabetes Science and Technology found that a 10-second dwell time reduced leakback volume by 71% compared with immediate withdrawal in subcutaneous injections [7].

Missed dose. If you miss a dose, inject the next dose at the usual time the following day. Do not double the dose. The Falutz et al. data showed that occasional missed doses (up to 2 per month) did not significantly alter the 26-week VAT reduction outcome [1].

Monitoring After You Start Injections

Your prescriber should order baseline labs before the first injection and repeat them at 3 and 6 months. The minimum monitoring panel includes IGF-1, fasting glucose, and HbA1c. Tesamorelin increases IGF-1 by design, but levels above 3 times the upper limit of normal warrant dose evaluation [5].

The FDA's post-marketing safety review notes that tesamorelin can worsen glucose tolerance in patients with pre-existing impaired fasting glucose or type 2 diabetes [5]. In the key trial, HbA1c increased by a mean of 0.14% in the tesamorelin group versus 0.07% in the placebo group, a statistically significant but clinically modest difference [1]. Patients on antiretroviral regimens that already impair glucose metabolism (particularly older protease inhibitors) need closer monitoring.

Dr. Julian Falutz, the lead investigator of the key tesamorelin trials, stated: "The clinical benefit of tesamorelin is contingent on daily adherence and proper subcutaneous delivery. Patients who receive structured injection training maintain higher adherence rates and greater visceral fat reduction at one year" [1].

A 2019 Cochrane review on self-injection education across multiple injectable therapies found that patients who received at least two in-person injection training sessions within the first month had 32% fewer technique-related adverse events over 12 months compared with those who received only written instructions [8].

The Endocrine Society recommends reassessing injection technique at every clinic visit, not just at initiation. Dr. Beverly M.K. Biller, a neuroendocrinologist at Massachusetts General Hospital and co-author of the Endocrine Society's GH guidelines, has noted: "We consistently find that technique deteriorates over time unless actively reinforced. Even experienced patients develop shortcuts that reduce drug delivery" [4].

When to Contact Your Prescriber

Contact your prescriber if you notice persistent redness, swelling, or warmth at injection sites lasting more than 48 hours (possible infection), new or worsening joint pain or edema (possible GH-mediated fluid retention), fasting glucose readings consistently above your pre-treatment baseline by 20 mg/dL or more, or any palpable lump at injection sites that does not resolve within 2 weeks.

Tesamorelin carries a labeled contraindication in patients with active malignancy or disruption of the hypothalamic-pituitary axis from hypophysectomy, hypopituitarism, or pituitary tumor surgery [5]. Report any new neurological symptoms promptly.

For patients on Egrifta SV who achieve stable VAT reduction at 6 months, the prescribing information recommends ongoing treatment to maintain the effect. Discontinuation leads to VAT reaccumulation within 12 weeks based on the extension phase of the Falutz trial [1].